open access

Vol 16, No 1 (2020)
Review paper
Published online: 2020-02-28
Get Citation

Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck

Beata Jagielska, Elżbieta Sarnowska, Tomasz Sarnowski, Katarzyna Śmiałek-Kania, Janusz Siedlecki, Andrzej Kawecki
DOI: 10.5603/OCP.2020.0005
·
Oncol Clin Pract 2020;16(1):1-8.

open access

Vol 16, No 1 (2020)
REVIEW ARTICLES
Published online: 2020-02-28

Abstract

Adenoic cystic carcinoma (SACC, ACC) in the head and neck area, occurring in small and large salivary glands are relatively rare tumors, usually undergoing slow progression. ACC is characterized by a different clinical course compared to other cancers, with a long latency period, a tendency to form late, initially asymptomatic metastases and a small percentage of responses to systemic treatment. This article presents current recommendations for diagnostic procedures and treatment possibilities.

Abstract

Adenoic cystic carcinoma (SACC, ACC) in the head and neck area, occurring in small and large salivary glands are relatively rare tumors, usually undergoing slow progression. ACC is characterized by a different clinical course compared to other cancers, with a long latency period, a tendency to form late, initially asymptomatic metastases and a small percentage of responses to systemic treatment. This article presents current recommendations for diagnostic procedures and treatment possibilities.

Get Citation

Keywords

adenoid cystic carcinoma, ACC, SACC, head and neck

About this article
Title

Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 1 (2020)

Article type

Review paper

Pages

1-8

Published online

2020-02-28

DOI

10.5603/OCP.2020.0005

Bibliographic record

Oncol Clin Pract 2020;16(1):1-8.

Keywords

adenoid cystic carcinoma
ACC
SACC
head and neck

Authors

Beata Jagielska
Elżbieta Sarnowska
Tomasz Sarnowski
Katarzyna Śmiałek-Kania
Janusz Siedlecki
Andrzej Kawecki

References (68)
  1. Martínez-Rodríguez N, Leco-Berrocal I, Rubio-Alonso L, et al. Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: a meta-analytic study. Med Oral Patol Oral Cir Bucal. 2011; 16(7): e884–e889.
  2. Rinaldo A, Shaha AR, Pellitteri PK, et al. Management of malignant sublingual salivary gland tumors. Oral Oncol. 2004; 40(1): 2–5.
  3. Dillon PM, Chakraborty S, Moskaluk C, et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head & Neck. 2015; 38(4): 620–627.
  4. Monteiro D, Lino J, Bernardo T, et al. Adenoid cystic carcinoma of the head and neck: epidemiology and predictors of prognosis. Int J Head Neck Surg. 2013; 02(05): 165–173.
  5. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992; 164(6): 623–628.
  6. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001; 96(3): 149–158.
  7. Chummun S, McLean NR, Kelly CG, et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg. 2001; 54(6): 476–480.
  8. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 1974; 128(4): 512–520.
  9. Prasad AR, Savera AT, Gown AM, et al. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med. 1999; 123(9): 801–806, doi: 10.1043/0003-9985(1999)123<0801:TMIIBA>2.0.CO;2.
  10. Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol. 2013; 7(1): 17–22.
  11. Choi Y, Kim SB, Yoon D, et al. Clinical characteristics and prognostic factors of adenoid cystic carcinoma of the head and neck. Laryngoscope. 2013; 123(6): 1430–1438.
  12. Azumi N, Battifora H. The cellular composition of adenoid cystic carcinoma. An immunohistochemical study. Cancer. 1987; 60(7): 1589–1598, doi: 10.1002/1097-0142(19871001)60:7<1589::aid-cncr2820600729>3.0.co;2-u.
  13. Caselitz J, Schulze I, Seifert G. Adenoid cystic carcinoma of the salivary glands: an immunohistochemical study. J Oral Pathol. 1986; 15(6): 308–318.
  14. Adelstein DJ, Shlomo A, Koyfman A, et al. Biology and management of salivary gland cancers. Semin Radiat Oncol. 2012; 22(3): 245–253.
  15. Piotrowska-Seweryn A, Pietruszka K, Groszkiewicz K. Rak gruczołowo-torbielowaty regionu głowy i szyi — trudności diagnostyczne i metody leczenia. Otolaryngologia. 2017; 16(3): 88–93.
  16. Vila L, Liu H, Al-Quran S, et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol. 2009; 22(10): 1296–1302.
  17. Frierson HF, El-Naggar A, Welsh J, et al. Largescale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol. 2002; 161(4): 1315–1323.
  18. Marcinow A, Ozer E, Teknos T, et al. Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: a single institutional experience at a tertiary care center. Head Neck. 2014; 36(12): 1705–1711.
  19. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res. 2004; 105(2-4): 442–447.
  20. Daa T, Kashima K, Kaku N, et al. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol. 2004; 17(12): 1475–1482.
  21. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 95(5): 586–593.
  22. Kowalski PJ, Paulino A. Perineural invasion in adenoid cystic carcinoma: Its causation/promotion by brain-derived neurotrophic factor. Hum Pathol. 2002; 33(9): 933–936.
  23. Cho KJ, Lee SS, Lee YS. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck. 1999; 21(5): 414–419.
  24. Gibbons MD, Manne U, Carroll WR, et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope. 2001; 111(8): 1373–1378.
  25. Chiang CP, Chen CH, Liu BY, et al. Expression of transforming growth factor-alpha in adenoid cystic carcinoma of the salivary gland. J Formos Med Assoc. 2001; 100(7): 471–477.
  26. Dori S, Trougouboff P, David R, et al. Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol. 2000; 36(5): 450–453.
  27. Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997; 389(6653): 856–860.
  28. Zhou XF, Rush RA. Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neuroscience. 1996; 74(4): 945–951.
  29. Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013; 45(7): 791–798.
  30. Persson F, Fehr A, Sundelin K, et al. Studies of genomic imbalances and the MYB-NFIB gene fusion in polymorphous low-grade adenocarcinoma of the head and neck. Int J Oncol. 2012; 40(1): 80–84.
  31. Persson M, Andrén Y, Moskaluk CA, et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer. 2012; 51(8): 805–817.
  32. Del Negro A, Ichihara E, Tincani AJ, et al. Laryngeal adenoid cystic carcinoma: case report. Sao Paulo Med J. 2007; 125(5): 295–296.
  33. Singh FM, Mak SY, Bonington SC, et al. Pattents of spread of head and neck adenoid cystic carcinoma. Clin Radiol. 2015; 70(6): 644–653.
  34. Gao M, Hao Y, Huang MX, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013; 42(8): 923–928.
  35. Sung MW, Kim K, Kim JW, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003; 129(11): 1193.
  36. Matsuba HM, Spector G, Thawley S, et al. Adenoid cystic salivary gland carcinoma: a histopathologic review of treatment failure patterns. Cancer. 1986; 57(3): 519–524, doi: 10.1002/1097-0142(19860201)57:3<519::aid-cncr2820570319>3.0.co;2-v.
  37. North CA, Lee DJ, Piantadosi S, et al. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1990; 18(6): 1319–1326.
  38. Terhaard CHJ, Lubsen H, Rasch CRN, et al. Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005; 61(1): 103–111.
  39. Bissett RJ, Fitzpatrick PJ. Malignant submandibular gland tumors. A review of 91 patients. Am J Clin Oncol. 1988; 11(1): 46–51.
  40. Miglianico L, Eschwege F, Marandas P, et al. Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys. 1987; 13(5): 673–678.
  41. Simpson JR, Thawley SE, Matsuba HM. Adenoid cystic salivary gland carcinoma: treatment with irradiation and surgery. Radiology. 1984; 151(2): 509–512.
  42. Mendenhall WM, Morris C, Amdur R, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004; 26(2): 154–162.
  43. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993; 27(2): 235–240.
  44. Samant S, Brekel Mv, Kies M, et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck. 2011; 34(9): 1263–1268.
  45. https://clinicaltrials.gov/ct2/show/NCT01220583 (29.04.2019).
  46. Chintakuntlawar AV, Okuno S, Price K. Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck. 2016; 1(1).
  47. Lagha A, Chraiet N, Ayadi M, et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol. 2012; 4(1).
  48. Laurie SA, Ho A, Fury M, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011; 12(8): 815–824.
  49. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24(17): 2673–2678.
  50. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001; 91(3): 541–547, doi: 10.1002/1097-0142(20010201)91:3<541::aid-cncr1032>3.0.co;2-y.
  51. Gedlicka C, Schüll B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs. 2002; 13(5): 491–495.
  52. Laurie SA, Siu L, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer. 2010; 116(2): 362–368.
  53. Gilbert J, Li Yi, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006; 28(3): 197–204.
  54. Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999; 12(10): 956–960.
  55. Ross PJ, Teoh EM, A'hern RP, et al. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol). 2009; 21(4): 311–314.
  56. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005; 23(3): 585–590.
  57. Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007; 43(1): 33–36.
  58. Guigay JM, Bidault F, Temam S, et al. Antitumor activity of imatinib in progressive highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. J Clin Oncol. 2007; 25(18_suppl): 6086.
  59. Chae YK, Chung SuY, Davis AA, et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015; 6(35): 37117–37134.
  60. Agulnik M, Cohen EWE, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25(25): 3978–3984.
  61. Jakob JA, Kies MS, Glisson BS, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015; 37(5): 644–649.
  62. Jensen AD, Nikoghosyan A, Hinke A, et al. Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux®and particle therapy]. BMC Cancer. 2011; 11(1).
  63. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45(7): 574–578.
  64. Hitre E, Budai B, Takácsi-Nagy Z, et al. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer. 2013; 109(5): 1117–1122.
  65. Eaton KD, Goulart B, Santana-Davila R, et al. Phase II trial of eribulin for recurrent or metastatic salivary gland cancers. J Clin Oncol. 2016; 34(15_suppl): 6095.
  66. Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010; 34(5): 599–608.
  67. Tchekmedyian V, Sherman E, Dunn L, et al. A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2018; 36(15_suppl): 6022–6022.
  68. Locati L, Galbiati D, Calareso G, et al. Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936). J Clin Oncol. 2018; 36(15_suppl): 6086.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl